Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laure Elens

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
Pharmacogenomics|July 11, 2013
CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipientsViolette M G J Gijsen, Ron Hn van Schaik, Laure Elens, et al.
Therapeutic Drug Monitoring|April 16, 2016
SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn InfantsMaja Matic, Saskia N de Wildt, Laure Elens, et al.
Pharmacogenetics and Genomics|September 28, 2011
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam StudyLaure Elens, Matthijs L Becker, Vincent Haufroid, et al.
Drug Metabolism and Personalized Therapy|October 3, 2014
No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemiaGeorgia Ragia, Vana Kolovou, Anna Tavridou, et al.
Pharmacogenomics|August 22, 2014
Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approachVanessa Guy-Viterbo, Henry Baudet, Laure Elens, et al.
British Journal of Pharmacology|February 5, 2025
Silencing drug transporters in human primary muscle cells modulates atorvastatin pharmacokinetics: A pilot studyEmilia Hoste, Louise Deldicque, Giulio G Muccioli, et al.
The Journal of Infectious Diseases|March 4, 2025
Dolutegravir and Risk of Neuropsychiatric Adverse Events: a Pharmacogenetic StudyJulien De Greef, Jean Cyr Yombi, Anne Vincent, et al.
Renal Failure|February 4, 2015
Association of CYP3A variants with kidney transplant outcomesCarol Traynor, Peter Conlon, Paul J Phelan, et al.
Clinical Pharmacology and Therapeutics|October 17, 2023
Tacrolimus Pharmacokinetics is Associated with Gut Microbiota Diversity in Kidney Transplant Patients: Results from a Pilot Cross-Sectional StudyAlexandra L Degraeve, Laure B Bindels, Vincent Haufroid, et al.
Pharmacogenomics|January 19, 2013
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycinLaure Elens, Annemieke Nieuweboer, Stephen J Clarke, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Pharmacogenomics|July 11, 2013
CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipientsViolette M G J Gijsen, Ron Hn van Schaik, Laure Elens, et al.
Therapeutic Drug Monitoring|April 16, 2016
SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn InfantsMaja Matic, Saskia N de Wildt, Laure Elens, et al.
Pharmacogenetics and Genomics|September 28, 2011
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam StudyLaure Elens, Matthijs L Becker, Vincent Haufroid, et al.
Drug Metabolism and Personalized Therapy|October 3, 2014
No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemiaGeorgia Ragia, Vana Kolovou, Anna Tavridou, et al.
Pharmacogenomics|August 22, 2014
Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approachVanessa Guy-Viterbo, Henry Baudet, Laure Elens, et al.
British Journal of Pharmacology|February 5, 2025
Silencing drug transporters in human primary muscle cells modulates atorvastatin pharmacokinetics: A pilot studyEmilia Hoste, Louise Deldicque, Giulio G Muccioli, et al.
The Journal of Infectious Diseases|March 4, 2025
Dolutegravir and Risk of Neuropsychiatric Adverse Events: a Pharmacogenetic StudyJulien De Greef, Jean Cyr Yombi, Anne Vincent, et al.
Renal Failure|February 4, 2015
Association of CYP3A variants with kidney transplant outcomesCarol Traynor, Peter Conlon, Paul J Phelan, et al.
Clinical Pharmacology and Therapeutics|October 17, 2023
Tacrolimus Pharmacokinetics is Associated with Gut Microbiota Diversity in Kidney Transplant Patients: Results from a Pilot Cross-Sectional StudyAlexandra L Degraeve, Laure B Bindels, Vincent Haufroid, et al.
Pharmacogenomics|January 19, 2013
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycinLaure Elens, Annemieke Nieuweboer, Stephen J Clarke, et al.
Pageof 9